New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - September 8, 2017 Category: Pharmaceuticals Source Type: news
New Data Change Metastatic Prostate Cancer Treatment Paradigm New Data Change Metastatic Prostate Cancer Treatment Paradigm
Dr Chodak reviews results of the LATITUDE trial, which compared ADT alone versus ADT with abiraterone acetate plus prednisone.Medscape Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2017 Category: Consumer Health News Tags: Urology Commentary Source Type: news
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
The NDA contains data to support approval for YONSA, (abiraterone acetate) ultramicrosize tablets, for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Churchill Pharmaceuticals also announces positive results from the pivotal ST... Biopharmaceuticals, Oncology, FDA Churchill Pharmaceuticals, YONSA, abiraterone, Prostate Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 20, 2017 Category: Pharmaceuticals Source Type: news
Drugs Score Big Wins Against Lung, Prostate, Breast Cancers
CHICAGO (AP) — Drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There’s even a “uni-drug” that may fight many forms of the disease.
What’s striking: The drugs are beneficial in some cases for more than a year, much longer than the few months many new drugs provide. Here are highlights from the world’s largest cancer meeting, the American Society of Clinical Oncology conference in Chicago.
PROSTATE CANCER
Janssen Biotech’s Zytiga improved survival and delayed cancer growth for 18 months when added to standar...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 5, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Breast Cancer Health News Prostate Cancer Source Type: news
Early use of J & J's Zytiga extends prostate cancer survival
CHICAGO (Reuters) - Adding Johnson& Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Abiraterone/ADT Combo Increased Prostate Cancer Survival
Combined therapy with abiraterone acetate/prednisone plus ADT significantly improved overall survival and radiographic progression-free survival among men with metastatic hormone-naive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Prostate Cancer News Source Type: news
Drug Extends Lives of Patients With Advanced Prostate Cancer: Studies
SATURDAY, June 3, 2017 -- Men with advanced prostate cancer might be able to avoid chemotherapy by taking an additional anti-testosterone pill along with standard hormone therapy, a pair of new clinical trials show.
The drug, abiraterone (Zytiga),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 3, 2017 Category: General Medicine Source Type: news
Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Na ïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 3, 2017 Category: Pharmaceuticals Source Type: news
Study shows early Zytiga use improves prostate cancer survival
CHICAGO (Reuters) - Adding Johnson& Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the risk of death for men newly diagnosed with prostate cancer that had spread to other parts of the body, according to new trial results. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Churchill Pharmaceuticals Announces Submission of NDA for Yonsa (abiraterone acetate) Novel Oral Formulation of Prostate Cancer Treatment
King of Prussia, PA., May 23, 2017 Churchill Pharmaceuticals, LLC (Churchill) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Yonsa (abiraterone acetate), an improved ultramicrosize... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 23, 2017 Category: Drugs & Pharmacology Source Type: news
ASCO 2017: Janssen to Present 19 Abstracts in Prostate Cancer and a Spectrum of Blood Cancers; Includes Data on Abiraterone Acetate, Daratumumab and Ibrutinib
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 18, 2017 Category: Pharmaceuticals Source Type: news
Trial: Abiraterone acetate responses even after initial hormone therapy failure
(University of Colorado Anschutz Medical Campus) Results of a 40-person clinical trial published in JAMA Oncology show that 13 percent of prostate cancer patients deemed 'hormone refractory' did, in fact, have strong responses to treatment with the next-generation hormonal drug abiraterone acetate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2017 Category: Global & Universal Source Type: news
Low-Fat Meal May Boost Costly Cancer Drug
FRIDAY, Feb. 17, 2017 -- Eating a low-fat meal when taking an expensive prostate cancer drug can cut the cost of the drug by three-quarters, a new study indicates. " We know this drug [Zytiga] is absorbed much more efficiently when taken with food, " ... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 17, 2017 Category: Journals (General) Source Type: news
Zytiga (Abiraterone Acetate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 31, 2016 Category: Drugs & Pharmacology Source Type: news
Abiraterone Acetate in Metastatic CRPCAbiraterone Acetate in Metastatic CRPC
Abiraterone acetate therapy for metastatic castration-resistant prostate cancer has shown efficacy in clinical trials, but are those same results achieved in real-world clinical practice? BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
